UNASSIGNED: Despite significant improvement in the management of @entity731 , this slowly progressing disease continues to affect countless @entity1 around the world. Recently, the mechanistic target of @entity3446 ( @entity3470 ) has been identified as a pre-eminent factor in the development of @entity731 . @entity3470 is a constitutively active kinase found in two different multiprotein complexes, @entity13407 and @entity15025 . Pharmacological interventions with a class of macrolide immunosuppressive drugs, called rapalogs, have shown undeniable evidence of the value of @entity13407 inhibition to prevent the development of @entity731 in several animal models. Rapalog-eluting stents have also shown extraordinary results in @entity1 , even though the exact mechanism for this anti- @entity731 effect remains elusive. Unfortunately, rapalogs are known to trigger diverse undesirable effects owing to @entity13407 resistance or @entity15025 inhibition. These adverse effects include dyslipidaemia and insulin resistance, both known triggers of @entity731 . Several strategies, such as combination therapy with @entity6817 and @entity2449 , have been suggested to oppose rapalog-mediated adverse effects. @entity6817 and @entity2449 are known to inhibit @entity13407 indirectly via 5' @entity860 -activated protein kinase (AMPK) activation and may hold the key to exploit the full potential of @entity13407 inhibition in the treatment of @entity731 . Intermittent regimens and dose reduction have also been proposed to improve rapalog's @entity13407 selectivity, thereby reducing @entity15025 -related side effects.

Potential therapeutic effects of XXXX inhibition in @entity731 .

@entity1 :: ('9606', 'Species') :: ['humans', 'patients'] @entity15025 :: ('74343(Tax:10090)', 'Gene') :: ['mTORC2'] @entity860 :: ('MESH:D000249', 'Chemical') :: ['adenosine monophosphate'] @entity13407 :: ('382056(Tax:10090)', 'Gene') :: ['mTORC1'] @entity3446 :: ('MESH:D020123', 'Chemical') :: ['rapamycin'] @entity3470 :: ('21977(Tax:10090)', 'Gene') :: ['mTOR'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic', 'atherosclerosis', 'atherosclerotic plaques'] @entity6817 :: ('D019821', 'Chemical') :: ['Statins', 'statins'] @entity2449 :: ('MESH:D008687', 'Chemical') :: ['metformin']
@entity3470 :: (21977(Tax:10090),Gene) :: ['mTOR']
